Using genomic tools, researchers have uncovered genetic changes associated with a form of leukemia that recurs in some children.
The findings, reported last month in Cancer Cell, suggest that some of these young patients may benefit from targeted drugs that are available but currently not used to treat this particular form of the disease. Read more > >
Dr. Louis Staudt of NCI's Center for Cancer Research and colleagues have confirmed that Burkitt lymphoma is molecularly distinct from other types of non-Hodgkin lymphoma. This discovery will help identify promising new targets for treatment.
- FDA Approves First Drug Developed for Children with Rare Brain Tumor
- New Treatment for Severe Neutropenia Approved
- FDA Approves Drug to Treat Rare Type of Leukemia
- New Website Highlights NCI-Designated Cancer Centers
- 2011/2012 Cancer Trends Progress Report Available
- Website for NCI's Geographic Information Systems & Science Updated
- In Memoriam: International Cancer Researcher Gregory T. O'Conor
- Cyber-Seminar: Bridging Cancer Research and Clinical Practice
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.